TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
|
LATEST DATA IN THE GLIOBLASTOMA STUDY ASCO 2022 Poster: Full top-line results from NOX-A12 Phase 1/2 GLORIA trial in GBM presented at the 2022 ASCO Annual Meeting |
Press ReleaseBerlin, Germany 2022, September 20 06:00 p.m. TME Pharma announces upcoming presentation at the Society for Neuro-Oncology Annual Meeting 2022 2022, August 26 08:00 a.m. Safety confirmed of NOX-A12 and pembrolizumab combination in GLORIA Phase 1/2 brain cancer study 2022, August 03 08:00 a.m. TME Pharma announces enrollment of first patient in pembrolizumab expansion arm of NOX-A12 GLORIA Phase 1/2 brain cancer clinical trial |
EventsBIO-Europe
Aram Mangasarian, Ewelina Staniuk SNO Annual Meeting 2022
Poster Presentation by Dr. Frank Giordano on Nov 18, Friday, 07:30 – 09:30 p.m. EST |